Immix Biopharma, Inc.
$8.44
+0.90%Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -9.5).
Valuation inputs: P/E -9.5, earnings yield N/A, momentum +0.9%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -31.4%, ROIC -28.7%).
Profitability stack: net margin 0.0%, ROE -31.4%, ROIC -28.7%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +10.5%, momentum +0.9%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Immix Biopharma, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Immix Biopharma, Inc. Fair Value Envelope
No Revenue Data
IMMX has not reported any revenue values in the available annual periods.
Immix Biopharma, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
IMMX has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
IMMX has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
IMMX has not reported any net profit margin values in the available annual periods.
Immix Biopharma, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Immix Biopharma, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Immix Biopharma, Inc. Street Expectations Map
Wall Street analysts project that IMMX stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 17.00, with estimates ranging from a low of 14.00 to a high of 20.00.
The consensus 1-year price target stands at 17.00, with estimates ranging from a low of 14.00 to a high of 20.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.
Analyst Conviction
Positive outlook with reasonable agreement. Analysts generally optimistic about prospects with manageable uncertainty.
Market Sentiment Insight
Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.
Immix Biopharma, Inc. Insider Positioning
During the last 12 months, insiders have purchased $2.00M and sold $633K worth of IMMX shares, resulting in $1.36M of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
1.5K
10.04K
0
0.00
+10K
+$10K
6-9 Months
5.1K
10.17K
316.5K
632.91K
-623K
-$623K
9-12 Months
882.4K
1.98M
0
0.00
+2.0M
+$1.98M
Top Buyers
Morris Gabriel S
Director, Officer: Cfo
$777K
Rachman Ilya M
Director, Officer: Ceo And Chairman
$777K
Buchan Jane
Director
$74K
Chudnovsky Yekaterina
Director, 10 Percent Owner:
$74K
Ng Carey
Director
$74K
Top Sellers
Chang Nancy T
Director
$633K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $1.36M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Insider Participation
5 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
No Dividend Yield Data
IMMX has not reported any dividend yield values in the available annual periods.
immx Dividend History
Learning Layer
Related Guides
Build conviction on IMMX by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.